|
1
|
Gucalp A, Gupta GP, Pilewskie ML, Sutton
EJ and Norton L: Advances in managing breast cancer: A clinical
update. F1000Prime Rep. 6(66)2014.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Wilson TR, Longley DB and Johnston PG:
Chemoresistance in solid tumours. Ann Oncol. 17 (Suppl
10):x315–x324. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Prihantono and Faruk M: Breast
cancer resistance to chemotherapy: When should we suspect it and
how can we prevent it? Ann Med Surg (Lond).
70(102793)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Marquette C and Nabell L:
Chemotherapy-resistant metastatic breast cancer. Curr Treat Options
Oncol. 13:263–275. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wang X, Zhang H and Chen X: Drug
resistance and combating drug resistance in cancer. Cancer Drug
Resist. 2:141–160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Moulder S: Intrinsic resistance to
chemotherapy in breast cancer. Womens Health (Lond). 6:821–830.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Crea F, Nobili S, Paolicchi E, Perrone G,
Napoli C, Landini I, Danesi R and Mini E: Epigenetics and
chemoresistance in colorectal cancer: An opportunity for treatment
tailoring and novel therapeutic strategies. Drug Resist Updat.
14:280–296. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Barrett-Lee PJ, Dixon JM, Farrell C, Jones
A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A and
Verrill MW: Expert opinion on the use of anthracyclines in patients
with advanced breast cancer at cardiac risk. Ann Oncol. 20:816–827.
2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shi Y, Bieerkehazhi S and Ma H:
Next-generation proteasome inhibitor oprozomib enhances sensitivity
to doxorubicin in triple-negative breast cancer cells. Int J Clin
Exp Pathol. 11:2347–2355. 2018.PubMed/NCBI
|
|
10
|
Smith L, Watson MB, O'Kane SL, Drew PJ,
Lind MJ and Cawkwell L: The analysis of doxorubicin resistance in
human breast cancer cells using antibody microarrays. Mol Cancer
Ther. 5:2115–2120. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
AbuHammad S and Zihlif M: Gene expression
alterations in doxorubicin resistant MCF7 breast cancer cell line.
Genomics. 101:213–220. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li X, Lu Y, Liang K, Liu B and Fan Z:
Differential responses to doxorubicin-induced phosphorylation and
activation of Akt in human breast cancer cells. Breast Cancer Res.
7:R589–R597. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH,
Kim BW, Choi HY, Jeong MY and Cho SG: Interplay between PI3K/Akt
and MAPK signaling pathways in DNA-damaging drug-induced apoptosis.
Biochim Biophys Acta. 1763:958–968. 2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shukla A, Hillegass JM, MacPherson MB,
Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR and Mossman BT:
Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to
doxorubicin. Mol Cancer. 9(314)2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shi Y, Moon M, Dawood S, McManus B and Liu
PP: Mechanisms and management of doxorubicin cardiotoxicity. Herz.
36:296–305. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Elmadany N, Khalil E, Vaccari L, Birarda
G, Yousef I and Abu-Dahab R: Antiproliferative activity of the
combination of doxorubicin/quercetin on MCF7 breast cancer cell
line: A combined study using colorimetric assay and synchrotron
infrared microspectroscopy. Infrared Phys Technol. 95:141–147.
2018.
|
|
17
|
Yang F, Teves SS, Kemp CJ and Henikoff S:
Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys
Acta. 1845:84–89. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Barbeau D, Persoons R, Marques M, Hervé C,
Laffitte-Rigaud G and Maitre A: Relevance of urinary
3-hydroxybenzo(a)pyrene and 1-hydroxypyrene to assess exposure to
carcinogenic polycyclic aromatic hydrocarbon mixtures in metallurgy
workers. Ann Occup Hyg. 58:579–590. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huang ZP, Liu XJ, Zou BX, Wang LG and Zhou
T: The complete recanalization of PICC-related venous thrombosis in
cancer patients: A series of case reports. Exp Ther Med. 6:411–412.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hashemzaei M, Delarami Far A, Yari A,
Heravi RE, Tabrizian K, Taghdisi SM, Sadegh SE, Tsarouhas K,
Kouretas D, Tzanakakis G, et al: Anticancer and apoptosis-inducing
effects of quercetin in vitro and in vivo. Oncol Rep.
38:819–828. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Slighoua M, Amrati FE, Chebaibi M, Mahdi
I, Al Kamaly O, El Ouahdani K, Drioiche A, Saleh A and Bousta D:
Quercetin and ferulic acid elicit estrogenic activities in vivo and
in silico. Molecules. 28(5112)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Notas G, Nifli AP, Kampa M, Pelekanou V,
Alexaki VI, Theodoropoulos P, Vercauteren J and Castanas E:
Quercetin accumulates in nuclear structures and triggers specific
gene expression in epithelial cells. J Nutr Biochem. 23:656–666.
2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liu Y, Liu C, Tang C and Yin C: Dual
stimulus-responsive chitosan-based nanoparticles co-delivering
doxorubicin and quercetin for cancer therapy. Mater Lett.
305(130826)2021.
|
|
24
|
Henidi HA, Al-Abbasi FA, El-Moselhy MA,
El-Bassossy HM and Al-Abd AM: Despite blocking doxorubicin-induced
vascular damage, quercetin ameliorates its antibreast cancer
activity. Oxid Med Cell Longev. 2020(8157640)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen JY, Hu RY and Chou HC:
Quercetin-induced cardioprotection against doxorubicin
cytotoxicity. J Biomed Sci. 20(95)2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li S, Yuan S, Zhao Q, Wang B, Wang X and
Li K: Quercetin enhances chemotherapeutic effect of doxorubicin
against human breast cancer cells while reducing toxic side effects
of it. Biomed Pharmacother. 100:441–447. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Li SZ, Li K, Zhang JH and Dong Z: The
effect of quercetin on doxorubicin cytotoxicity in human breast
cancer cells. Anticancer Agents Med Chem. 13:352–355.
2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang G, Zhang J, Liu L, Sharma S and Dong
Q: Quercetin potentiates doxorubicin mediated antitumor effects
against liver cancer through p53/Bcl-xl. PLoS One.
7(e51764)2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shu Y, Xie B, Liang Z and Chen J:
Quercetin reverses the doxorubicin resistance of prostate cancer
cells by downregulating the expression of c-met. Oncol Lett.
15:2252–2258. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Huang CF, Liu SH, Ho TJ, Lee KI, Fang KM,
Lo WC, Liu JM, Wu CC and Su CC: Quercetin induces tongue squamous
cell carcinoma cell apoptosis via the JNK activation-regulated
ERK/GSK-3α/β-mediated mitochondria-dependent apoptotic signaling
pathway. Oncol Lett. 23(78)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Schuurhuis GJ, Van Heijningen TH,
Cervantes A, Pinedo HM, de Lange JH, Keizer HG, Broxterman HJ, Baak
JP and Lankelma J: Changes in subcellular doxorubicin distribution
and cellular accumulation alone can largely account for doxorubicin
resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug
resistant tumour cells. Br J Cancer. 68:898–908. 1993.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang X, Li Y, Fan GF, Zhang TY, Sun B and
Fan PS: Effect of verapamil in the reversal of doxorubicin
chemotherapy resistance in advanced gastric cancer. Eur Rev Med
Pharmacol Sci. 24:7753–7763. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Rogan AM, Hamilton TC, Young RC, Klecker
RW Jr and Ozols RF: Reversal of adriamycin resistance by verapamil
in human ovarian cancer. Science. 224:994–996. 1984.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bellamy WT, Dalton WS, Kailey JM, Gleason
MC, McCloskey TM, Dorr RT and Alberts DS: Verapamil reversal of
doxorubicin resistance in multidrug-resistant human myeloma cells
and association with drug accumulation and DNA damage. Cancer Res.
48:6365–6370. 1988.PubMed/NCBI
|
|
36
|
AlQudah DA, Zihlif MA and Taha MO:
Ligand-based modeling of diverse aryalkylamines yields new potent
P-glycoprotein inhibitors. Eur J Med Chem. 110:204–223.
2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Li J, Poi MJ and Tsai MD: Regulatory
mechanisms of tumor suppressor P16(INK4A) and their relevance to
cancer. Biochemistry. 50:5566–5582. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Srivastava S, Somasagara RR, Hegde M,
Nishana M, Tadi SK, Srivastava M, Choudhary B and Raghavan SC:
Quercetin, a natural flavonoid interacts with DNA, arrests cell
cycle and causes tumor regression by activating mitochondrial
pathway of apoptosis. Sci Rep. 6(24049)2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Suh DK, Lee EJ, Kim HC and Kim JH:
Induction of G(1)/S phase arrest and apoptosis by quercetin in
human osteosarcoma cells. Arch Pharm Res. 33:781–785.
2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ,
Yoo YD, Kim TW, Lee YS and Lee SJ: Induction of cell cycle arrest
and apoptosis in human breast cancer cells by quercetin. Int J
Oncol. 19:837–844. 2001.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhang M, Zhang H, Tang F, Wang Y, Mo Z,
Lei X and Tang S: Doxorubicin resistance mediated by cytoplasmic
macrophage colony-stimulating factor is associated with switch from
apoptosis to autophagic cell death in MCF-7 breast cancer cells.
Exp Biol Med (Maywood). 241:2086–2093. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Torgovnick A and Schumacher B: DNA repair
mechanisms in cancer development and therapy. Front Genet.
6(157)2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Roy R, Chun J and Powell SN: BRCA1 and
BRCA2: Different roles in a common pathway of genome protection.
Nat Rev Cancer. 12:68–78. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Tassone P, Tagliaferri P, Perricelli A,
Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F,
Boland CR and Venuta S: BRCA1 expression modulates chemosensitivity
of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer.
88:1285–1291. 2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Quinn JE, James CR, Stewart GE, Mulligan
JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH and Harkin
DP: BRCA1 mRNA expression levels predict for overall survival in
ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420.
2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kundur S, Prayag A, Selvakumar P, Nguyen
H, McKee L, Cruz C, Srinivasan A, Shoyele S and Lakshmikuttyamma A:
Synergistic anticancer action of quercetin and curcumin against
triple-negative breast cancer cell lines. J Cell Physiol.
234:11103–11118. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Alves CL, Elias D, Lyng MB, Bak M and
Ditzel HJ: SNAI2 upregulation is associated with an aggressive
phenotype in fulvestrant-resistant breast cancer cells and is an
indicator of poor response to endocrine therapy in estrogen
receptor-positive metastatic breast cancer. Breast Cancer Res.
20(60)2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Côme C, Magnino F, Bibeau F, De Santa
Barbara P, Becker KF, Theillet C and Savagner P: Snail and slug
play distinct roles during breast carcinoma progression. Clin
Cancer Res. 12:5395–5402. 2006.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lin M, Zhang Z, Gao M, Yu H, Sheng H and
Huang J: MicroRNA-193a-3p suppresses the colorectal cancer cell
proliferation and progression through downregulating the PLAU
expression. Cancer Manag Res. 11:5353–5363. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ai C, Zhang J, Lian S, Ma J, Győrffy B,
Qian Z, Han Y and Feng Q: FOXM1 functions collaboratively with PLAU
to promote gastric cancer progression. J Cancer. 11:788–794.
2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Hoca M, Becer E, Kabadayı H, Yücecan S and
Vatansever HS: The effect of resveratrol and quercetin on
epithelial-mesenchymal transition in pancreatic cancer stem cell.
Nutr Cancer. 72:1231–1242. 2020.PubMed/NCBI View Article : Google Scholar
|
